<DOC>
	<DOCNO>NCT00350831</DOCNO>
	<brief_summary>The purpose study assess safety tolerability KIT inhibitor XL820 give orally daily adult advance solid tumor .</brief_summary>
	<brief_title>Study XL820 Given Orally Daily Subjects With Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Subject histologically confirm solid tumor metastatic unresectable know effective measure exist longer effective , know therapy prolong survival Subject least 18 year old Subject ECOG performance status ≤ 2 Subject life expectancy &gt; 3 month Subject adequate organ marrow function In adrenocorticotropic hormone ( ACTH ) stimulation test , subject serum cortisol level ≥ 20 ug/dL ( 552 nmol/L ) 3090 minute injection ACTH Subject give write informed consent Sexually active subject ( male female ) must use accepted method contraception course study . Female subject childbearing potential must negative pregnancy test screening . Subject receive anticancer treatment within 30 day first dose XL820 , recover grade ≤ 1 adverse event due agent administer 30 day earlier Subject receive radiation ≥ 25 % his/her bone marrow within 30 day XL820 treatment Subject receive investigational agent within 30 day first dose XL820 Subject know brain metastasis Subject know uncontrolled intercurrent illness Subject pregnant lactating Subject know positive HIV Subject know allergy hypersensitivity component XL820 formulation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>Solid tumor</keyword>
</DOC>